Skip to main content

Advertisement

SpringerLink
Log in

Model for simulation of HIV/AIDS and cost-effectiveness of preventing non-tuberculous mycobacterial (MAC)-disease

  • Original Papers
  • Published:
The European Journal of Health Economics, formerly: HEPAC Aims and scope Submit manuscript

Abstract

Because most HIV-infected patients die of diseases caused by opportunistic pathogens, the prevention of these infections is an important clinical issue. Cost-containment in the healthcare system is a subject of high priority in public debate. Methods to determine cost-effectiveness of different therapeutic strategies are therefore needed to obtain valid data as the basis for decisions on cost reduction without a decrease in the quality of care. A disease state transition model based on a Markov process was developed to simulate the natural history of HIV infection and the acquired immunodeficiency syndrome (AIDS). Using this model survival time and treatment costs for every patient can be estimated and the results of alternative medications compared. We determined the cost-effectiveness (per life-year saved, LYS) of different strategies for prevention of Mycobacterium avium complex infections in AIDS patients whose treatment regimens include protease inhibitors. The cost-effectiveness ratios for treatment strategies vary from €13,510 to €46,152 per LYS without protease inhibitors and from €22,309 to €51,336 with protease inhibitors. When azithromycin, clarithromycin, and rifabutin were compared, azithromycin was the most cost-effective medication for preventing M. avium complex. The results were stable against a wide range of parameter variations concerning costs and incidence rates.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Levy JA (1998) HIV and the pathogenesis of AIDS. American Society for Microbiology: Washington

    Google Scholar 

  2. Hoover DR et al (1993) Clinical manifestations in the era of Pneumocystis prophylaxis. N Engl J Med 329:1922–1926

    Article  CAS  PubMed  Google Scholar 

  3. Horsburgh, JR CR, Havlik JA, Ellis DA, Kennedy E, Fann SA, Dubois RE, Thompson SE (1991) Survival of patients with acquired immune deficiency syndrome and disseminated Mycobacterium avium complex infection with and without antimycobacterial chemotherapy. Am Rev Respir Dis 144:557–559

    PubMed  Google Scholar 

  4. Chaisson RE, Moore RD, Richman DD, Keruly J, Creagh T (1992) Incidence and natural history of Mycobacterium avium complex infections in patients with advanced human immunodeficiency virus disease treated with zidovudine. Am Rev Respir Dis 146:285–289

    CAS  PubMed  Google Scholar 

  5. Masur H (1993) Recommendations on prophylaxis and theray for disseminated Mycobacterium avium complex disease in patients infected with the human immunodeficiency virus. N Engl J Med 329:898–904

    Article  CAS  PubMed  Google Scholar 

  6. Centers for Disease Control and Prevention (1997) USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. MMWR Morb Mortal Wkly Rep 46:12

    Google Scholar 

  7. Hoffmann T (2002) Die gesundheitsökonomische Analyse medizinischer Maßnahmen. Lang, Frankfurt

  8. Freedberg KA, Scharfstein JA, Seage GR, Losina E, Weinstein MC, Craven DE, Paltiel AD (1998) The cost-effectiveness of preventing AIDS-related opportunistic infections. JAMA 279:130–136

    Article  CAS  PubMed  Google Scholar 

  9. Scharfstein JA, Paltiel AD, Weinstein MC, Seage GR, Losina E, Craven DE, Freedberg KA (1999) The cost-effectiveness of prophylaxis for Mycobacterium avium complex in AIDS. Int J Technol Assess Health Care 15:3:531–547

    Google Scholar 

  10. Freund YR, Dousman L, Mohaghehpour N (2002) Prophylactic clarithromycin to treat Mycobacterium avium in HIV patients receiving zidovudine may significantly increase mortality by suppressing lymphopoiesis and hematopoiesis. Int Immunopharmacol 2:1465–1475

    Article  CAS  PubMed  Google Scholar 

  11. Paltiel DA, Scharfstein JA, Seage GR, Losina E, Goldie SJ, Weinstein MC, Craven DE, Freedberg KA (1998) A Monte Carlo simulation of advanced HIV disease: application to prevention of CMV infection. Med Decis Making 18 [Suppl]:93–103

    Google Scholar 

  12. Gable CB, Tierce JC, Simison D, Ward D, Motte K (1996) Costs of HIV/AIDS at CD4 counts disease stages based on treatment protocols. J Acquir Immune Defic Syndr Hum Retrovirol 12:413–420

    CAS  PubMed  Google Scholar 

  13. EBM (1998) Einheitlicher Bewertungsmaßstab (EBM). Kassenärztlichen Bundesvereinigung: Cologne

  14. Anonymous (1998) Rote Liste, II. Aulendorf

  15. Exner-Freisfeld H, Stille W (1997) Kosten für die Behandlung von AIDS. Info. 3:51–55

    Google Scholar 

  16. Robert Koch Institut (1998) Langzeitbeobachtungen von Probanden mit bekanntem Zeitpunkt der HIV-Serokonversion. Epidemiol Bull 32:228–230

    Google Scholar 

  17. Miller DK, Homan SM (1994) Determining transition probabilities: confusion and suggestions. Med Decis Making 14:52–58

    CAS  PubMed  Google Scholar 

  18. Enger C, Graham N, Peng Y, Chmiel JS, Kingsley LA, Detels R, Munoz A (1996) Survival from early, intermediate and late stages of HIV infection. JAMA 275:1329–1334

    Article  CAS  PubMed  Google Scholar 

  19. Baillargeon J, Borucki M, Black SA, Dunn K (1999) Determinants of survival in HIV-positive patients. Int J STD AIDS 10:22–27

    Article  CAS  PubMed  Google Scholar 

  20. Dunne M, Fessle J, Kumar P, Dickenson G, Keiser P, Boulos M, Mogyros M, White Jr, AC, Cahn P, O’ Connor M, Lewi D, Green S, Tilles J, Hicks C, Bisset J, Schneider MME, Benner R (2000) A randomized, double-blind trial comparing azithromycin and clarithromycin in the treatment of disseminated Mycobacterium avium infection in patients with human immunodeficiency virus. Clin Infect Dis 31:1245–1252

    Article  CAS  PubMed  Google Scholar 

  21. Aberg JA, Wong MK, Flamm R, Notario GF, Jacobson (2001) Presence of macrolide resistance in respiratory flora of HIV-infected patients receiving either clarithromycin or azithromycin for Mycobacterium avium complex prophylaxis. HIV Clin Trials 2:453–459

    CAS  PubMed  Google Scholar 

  22. Bayoumi AM, Redelmeier DA (1998) Preventing Mycobacterium avium complex in patients who are using protease inhibitors: a cost effectiveness analysis. AIDS 12:1503–1512

    Article  CAS  PubMed  Google Scholar 

  23. Freund YR, Dousman L, Mohaghehpour N (2002) Prophylactic clarithromycin to treat Mycobacterium avium in HIV patients receiving zidovudine may significantly increase mortality by suppressing lymphopoiesis and hematopoiesis. Int Immunopharmacol 2:1465–1475

    Article  CAS  PubMed  Google Scholar 

  24. Sendi PP, Craig BA, Meier G, Pfluger D, Gafni A, Opravil M, Battegay M, Bucher HC (1999) Cost-effectiveness of azithromycin for preventing Mycobacterium avium complex infection in HIV-positive patients in the era of highly active antiretroviral therapy. J Antimicrob Chemother 44:811–817

    Article  CAS  PubMed  Google Scholar 

  25. Pierce M, Crampton S, Henry D, Heifets L, LaMarca A, Montecalvo M, Wormser GP, Jablonowski H, Jemsek J, Cynamon M, Yangoo BG, Notario G, Craft JC (1996) A randomized trial of clarithromycin as prophylaxis against disseminated Mycobacterium avium complex infection in patients with advanced acquired immunodeficiency syndrome. N Engl J Med 335:384–391

    Article  CAS  PubMed  Google Scholar 

  26. Havlir DV, Dube MP, Sattler FR, Forthal DN, Kemper CA, Dunne MW, Parenti DM, Lavelle JP, White AC, Witt MD, Bozzette SA, McCutchan JA (1996) Prophylaxis against disseminated Mycobacterium avium complex with weekly azithromycin, daily rifabutin, or both. N Engl J Med 335:392–398

    Article  CAS  PubMed  Google Scholar 

  27. Nightingale SD, Cameron DW, Gordin FM, Sullam PM, Cohn DL, Chaisson, RE, Eron LJ, Sparti PD, Bihari B, Kaufman DL (1993) Two controlled trials of rifabutin prophylaxis against Mycobacterium avium complex infection in AIDS. N Engl J Med 329:828–833

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institute of Health Economics and Clinical Epidemiology, University of Cologne, Germany

    Thomas Hoffmann & Helmut Brunner

  2. Am Leuschhof 8e, 51145, Cologne, Germany

    Thomas Hoffmann

Authors
  1. Thomas Hoffmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Helmut Brunner
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Thomas Hoffmann.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hoffmann, T., Brunner, H. Model for simulation of HIV/AIDS and cost-effectiveness of preventing non-tuberculous mycobacterial (MAC)-disease. HEPAC 5, 129–135 (2004). https://doi.org/10.1007/s10198-003-0211-4

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10198-003-0211-4

Keywords

Search

Navigation